Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962774 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
A Phase 1 study, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06962774 is a Phase 1 study that has completed, run by Alumis. The registered enrollment target is 16 participants.
The verdict
NCT06962774, a Phase 1 study, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.
Interventions
- DRUG ESK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06962774
The ClinicalTrials.gov registry entry for NCT06962774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ESK-001 is the first listed.
NCT06962774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06962774 about?
NCT06962774 is a clinical study titled "An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function". This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.
What is the current status of trial NCT06962774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-04-23. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT06962774?
The interventions under investigation include: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT06962774?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.